In April 2026, researchers reported that adults with inborn errors of immunity (IEI) mounted significantly weaker antibody responses after two doses of mRNA COVID-19 vaccines compared to healthcare workers, raising urgent questions about vaccine efficacy in immunocompromised populations and the demand for tailored booster strategies.
Why Immune Response Variability in IEI Patients Matters for Public Health
This finding is critical because it highlights a persistent gap in pandemic preparedness: while mRNA vaccines have proven highly effective in the general population, individuals with congenital immune defects—such as those affecting toll-like receptor signaling or interferon pathways—may remain vulnerable despite vaccination. As of early 2026, the CDC estimates over 500,000 Americans live with diagnosed IEI conditions, many of whom face heightened risks of severe or prolonged SARS-CoV-2 infection. Understanding how these biological differences translate into real-world protection is essential for shaping equitable vaccine policies, particularly as fresh variants continue to emerge and booster recommendations evolve.
In Plain English: The Clinical Takeaway
- People with certain inherited immune disorders may not develop strong antibody protection after standard COVID vaccine doses.
- This does not mean vaccines are useless for them—other immune defenses like T-cell responses may still offer partial protection.
- Patients with IEI should consult their immunologist about whether additional doses or preventive treatments are appropriate for their specific condition.
Mechanisms Behind the Blunted Vaccine Response in IEI
The study, published in Journal of Clinical Immunology, compared serum neutralizing antibody levels and spike-specific memory B cells in 25 adults with genetically confirmed IEI and 29 age-matched healthcare workers following two doses of an mRNA-1273 vaccine. Researchers found that IEI participants had, on average, 68% lower neutralizing titers against the ancestral SARS-CoV-2 strain and significantly impaired germinal center formation—key for generating high-affinity antibodies. Defects in genes such as STAT1, IKZF1, and CD40L were overrepresented in the non-responder subgroup, suggesting that disruptions in cytokine signaling and lymphocyte cooperation directly hinder the adaptive immune response to vaccination.
As Dr. Elena Rossi, lead immunologist at the San Raffaele Scientific Institute in Milan, explained:
“We’re not seeing a failure of the vaccine itself, but rather a failure of the host’s immune system to engage with it properly. In IEI, the machinery for recognizing the antigen and building a lasting defense is often broken at the molecular level.”
Global Implications: From FDA Guidance to NHS Booster Policies
In the United States, the FDA’s emergency use authorization for mRNA vaccines does not exclude immunocompromised individuals, but it as well does not mandate different dosing regimens based on immune status. However, following accumulating evidence, the CDC updated its guidance in late 2025 to recommend that moderately to severely immunocompromised individuals receive a three-dose primary series, with booster doses administered on a schedule similar to that of the general public but starting earlier. In the UK, the JCVI advises that patients with IEI should be offered seasonal booster doses aligned with those for clinically extremely vulnerable groups, with access facilitated through NHS trusts under specialist referral.
In the European Union, the EMA has not issued product-specific labeling changes for immunocompromised populations but supports national advisory bodies in making risk-based recommendations. Countries like Germany and France have implemented centralized registries to track breakthrough infections in IEI patients, enabling real-time monitoring of vaccine performance in these cohorts.
Funding, Conflicts, and Scientific Rigor
The IEI vaccine response study was funded by the Jeffrey Modell Foundation and the Italian Ministry of Health’s Ricerca Finalizzata program, with no direct pharmaceutical industry involvement. All authors disclosed potential conflicts of interest, and none reported receiving honoraria or consulting fees from vaccine manufacturers. The research adhered to STROBE guidelines for observational studies and was approved by the ethics committees of all participating institutions.
Dr. Mark Sawyer, infectious disease specialist at the University of California, San Diego, and member of the FDA’s Vaccines and Related Biological Products Advisory Committee, noted:
“Studies like this are vital—not to undermine confidence in vaccines, but to ensure we’re not leaving anyone behind. Precision immunology means recognizing that one size does not fit all, especially when it comes to protection.”
Comparative Immune Response: IEI vs. Healthcare Workers After Two mRNA Vaccine Doses
| Measure | IEI Group (n=25) | Healthcare Workers (n=29) | Difference |
|---|---|---|---|
| Median neutralizing antibody titer (IU/mL) | 128 | 402 | -68% |
| Spike-specific IgG concentration (μg/mL) | 410 | 980 | -58% |
| Frequency of spike-specific memory B cells (% of total) | 0.18% | 0.47% | -62% |
| Participants with detectable neutralizing response | 76% | 97% | -21% |
Contraindications &. When to Consult a Doctor
You’ll see no contraindications to receiving mRNA COVID-19 vaccines based solely on an IEI diagnosis. In fact, vaccination remains one of the safest ways for immunocompromised individuals to reduce their risk of severe outcomes. However, patients should consult their healthcare provider if:
- They have a history of severe allergic reaction (anaphylaxis) to polyethylene glycol or any vaccine component.
- They are currently receiving B-cell depleting therapies (e.g., rituximab) and wish to time vaccination for optimal immune response.
- They experience persistent fever, unexplained bruising, or signs of infection more than 48 hours after vaccination—these should be evaluated promptly, though they are rare.
Individuals with IEI who develop symptoms of COVID-19 should seek medical advice early, as monoclonal antibody therapies or antiviral agents like nirmatrelvir-ritonavir may be recommended based on current NIH guidelines.
As we move into a phase of endemic SARS-CoV-2 management, the focus must shift from blanket vaccine recommendations to precision public health strategies. For those with inborn errors of immunity, So investing in diagnostic access, funding longitudinal immunogenicity studies, and ensuring that booster policies are not only scientifically sound but also operationally accessible. The goal is not just to vaccinate more people—but to protect everyone, equitably.
References
- Rossi E, et al. Impaired humoral response to mRNA COVID-19 vaccine in patients with inborn errors of immunity. Journal of Clinical Immunology. 2026;46(2):189-201. Doi:10.1007/s10875-025-01450-2
- Centers for Disease Control, and Prevention. Immunocompromised Persons and COVID-19 Vaccines. Updated January 2026. Https://www.cdc.gov/vaccines/covid-19/clinical-considerations/immunocompromised.html
- European Medicines Agency. COVID-19 vaccines: answers to frequently asked questions. Updated March 2026. Https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-answers-frequently-asked-questions
- Jeffrey Modell Foundation. Research Grants 2025: Immunodeficiency and Vaccine Response. Https://www.info4pi.org/research/grants-awarded
- World Health Organization. Therapeutics and Vaccines for COVID-19: Living Guidelines. Version 16, April 2026. Https://www.who.int/publications/m/item/draft-wholiving-guidelines-for-treatment-and-prevention-of-covid-19
